Search

Your search keyword '"Conlon, Kevin"' showing total 28 results
Start Over Author "Conlon, Kevin" Journal blood
28 results on '"Conlon, Kevin"'

2. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Author

McDonnell, Scott R.P., Hwang, Steven R., Rolland, Delphine, Murga-Zamalloa, Carlos, Basrur, Venkatesha, Conlon, Kevin P., Fermin, Damian, Wolfe, Thomas, Raskind, Alexander, Ruan, Chunhai, Jiang, Jian-Kang, Thomas, Craig J., Hogaboam, Cory M., Burant, Charles F., Elenitoba-Johnson, Kojo S.J., and Lim, Megan S.

Published
2013
Full Text
View/download PDF

5. A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma

Author

Sahasrabuddhe, Anagh Anant, primary, Chen, Xiaofei, additional, Ma, Kaiyu, additional, Wu, Rui, additional, Kapoor, Richa, additional, Chhipa, Rishi Raj, additional, Zhang, Xiao, additional, Onder, Ozlem, additional, Wilmore, Joel, additional, Gaudette, Brian T., additional, Pillai, Vinodh, additional, Li, Marilyn M., additional, Ahn, Joon-Young, additional, Chung, Fuzon, additional, Szankasi, Philippe, additional, Basrur, Venkatesha, additional, Conlon, Kevin P, additional, Bailey, Nathanael G., additional, Hogaboam, Cory M, additional, Rottapel, Robert, additional, Kim, Junhyong, additional, Lopez, Cristina, additional, Seufert, Julian, additional, Schlesner, Matthias, additional, Siebert, Reiner, additional, Cancro, Michael P, additional, Allman, David, additional, Pagano, Michele, additional, Staudt, Louis M., additional, Lim, Megan S., additional, and Elenitoba-Johnson, Kojo S. J., additional

Published
2021
Full Text
View/download PDF

10. A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

Author

Phillips, Adrienne, primary, Fields, Paul, additional, Hermine, Olivier, additional, Ramos, Juan Carlos, additional, Beltran, Brady E, additional, Pereira, Juliana, additional, Brites, Carlos, additional, Wandroo, Farooq Ahmad, additional, Lill, Michael, additional, Feldman, Tatyana A, additional, Casanova, Luis, additional, Janakiram, Murali, additional, Meniane, Jean-Come, additional, Sawas, Ahmed, additional, Cook, Lucy B, additional, Kurman, Michael R., additional, George, Joyce, additional, Dwyer, Karen, additional, Leoni, Mollie, additional, Conlon, Kevin, additional, Taylor, Graham P., additional, Gonsky, Jason, additional, and Horwitz, Steven M., additional

Published
2016
Full Text
View/download PDF

11. N-Glycoproteomic Landscape of Human Lymphoid Cancers Reveals Novel Biomarkers and Potential Therapeutic Targets

Author

Rolland, Delphine CM, primary, Basrur, Venkatesha, additional, Jeon, Yoon Kyung, additional, McNeil-Schwalm, Carla, additional, Fermin, Damian, additional, Conlon, Kevin, additional, Tsou, Chih-Chiang, additional, Brown, Noah A, additional, Thomas, Dafydd G, additional, Bailey, Nathanael G., additional, Omenn, Gilbert S, additional, Nesvizhskii, Alexey I, additional, Lim, Megan S, additional, and Elenitoba-Johnson, Kojo SJ, additional

Published
2015
Full Text
View/download PDF

12. Comparative Phosphoproteomics Study Between Obinutuzumab (GA101) Vs. Rituximab (RTX) Against RTX Sensitive/Resistant Burkitt Lymphoma (BL): Differentially Phosphorylated B Cell Receptor, Fc-Gamma Receptor, Phagocytosis and Natural Killer Cell-Mediated Cytotoxicity Signaling Pathway Proteins

Author

Tiwari, Aradhana, primary, Rolland, Delphine CM, additional, Elmacken, Mona, additional, Ayello, Janet, additional, van de Ven, Carmella, additional, Basrur, Venkatesha, additional, Conlon, Kevin, additional, Fermin, Damine, additional, Barth, Matthew J., additional, Klein, Christian, additional, Elenitoba-Johnson, Kojo, additional, Lim, Megan S, additional, and Cairo, Mitchell S., additional

Published
2015
Full Text
View/download PDF

13. NPM-ALK Mediated Tyrosine Phosphorylation of ATP Citrate Lyase Regulates Lipid Metabolism and Promotes Oncogenesis of Anaplastic Large Cell Lymphoma

Author

Basappa, Johnvesly, primary, ElAzzouny, Mahmoud A, additional, Rolland, Delphine CM, additional, Velusamy, Thirunavukkarasu, additional, Hwang, Steven, additional, Basrur, Venkatesha, additional, Conlon, Kevin, additional, Zhao, Lili, additional, Bailey, Nathanael G., additional, Burant, Charles F, additional, Elenitoba-Johnson, Kojo SJ, additional, and Lim, Megan S, additional

Published
2015
Full Text
View/download PDF

16. A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Author

Awasthi, Aradhana, primary, Rolland, Delphine C.M., additional, Elmacken, Mona, additional, Reggio, Christopher, additional, Ayello, Janet, additional, van de Ven, Carmella, additional, Basrur, Venkatesha, additional, Conlon, Kevin, additional, Fermin, Damian, additional, Barth, Matthew J., additional, Elenitoba-Johnson, Kojo S.J., additional, Lim, Megan S, additional, and Cairo, Mitchell S., additional

Published
2014
Full Text
View/download PDF

19. Yttrium-90 Radiolabeled Daclizumab, An Anti-CD25 Monoclonal Antibody, Provides Effective Therapy for Refractory and Relapsed Hodgkin's Lymphoma,

Author

Waldmann, Thomas A., primary, Janik, John, additional, Morris, John C, additional, Conlon, Kevin, additional, O'Mahony, Deirdre, additional, Pittaluga, Stefania, additional, Jaffe, Elaine S., additional, Brechbiel, Martin, additional, Paik, Chang H, additional, Chen, Clara, additional, Whatley, Millie, additional, Fleisher, Thomas A, additional, White, Jeffrey, additional, Stewart, Donn, additional, Fioravanti, Suzanne, additional, Goldman, Carolyn, additional, Bryant, Bonita, additional, Decker, Jean, additional, Junghans, Richard, additional, and Carrasquillo, Jorge A., additional

Published
2011
Full Text
View/download PDF

24. Phase 1 trial of IL-15 transpresentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Author

Waldmann, Thomas A., Conlon, Kevin C., Stewart, Donn M., Worthy, TatYana A., Janik, John E., Fleisher, Thomas A., Albert, Paul S., Figg, William D., Spencer, Shawn D., Raffeld, Mark, Decker, Jean R., Goldman, Carolyn K., Bryant, Bonita R., Petrus, Michael N., Creekmore, Stephen P., and Morris, John C.

Abstract

In the present study, Hu-Mikβ1, a humanized mAb directed at the shared IL-2/IL-15Rβ subunit (CD122) was evaluated in patients with T-cell large granular lymphocytic (T-LGL) leukemia. Hu-Mikβ1 blocked the transpresentation of IL-15 to T cells expressing IL-2/IL-15Rβ and the common γ-chain (CD132), but did not block IL-15 action in cells that expressed the heterotrimeric IL-15 receptor in cis. There was no significant toxicity associated with Hu-Mikβ1 administration in patients with T-LGL leukemia, but no major clinical responses were observed. One patient who had previously received murine Mikβ1 developed a measurable Ab response to the infused Ab. Nevertheless, the safety profile of this first in-human study of the humanized mAb to IL-2/IL-15Rβ (CD122) supports its evaluation in disorders such as refractory celiac disease, in which IL-15 and its receptor have been proposed to play a critical role in the pathogenesis and maintenance of disease activity. The protocol is registered with www.clinicaltrials.govas number NCT 00076180.

Published
2013
Full Text
View/download PDF

25. Prolonged, Continuous Treatment of Hairy Cell Leukemia Patients With Recombinant Interferon-α2a

Author

Smith II, John W., Longo, Dan L., Urba, Walter J., Clark, Jeffrey W., Watson, Thelma, Beveridge, Joy, Conlon, Kevin C., Sznol, Mario, Creekmore, Stephen P., Alvord, W. Gregory, Lawrence, Jeffry B., and Steis, Ronald G.

Abstract

Interferons are not curative in hairy cell leukemia (HCL), and retreatment is necessary in most patients whose therapy is stopped. In an attempt to maintain or improve responses, we administered recombinant interferon-α2a (rlFN-α2a) continuously to patients with HCL who initially responded to this therapy. Of 53 evaluable patients enrolled in this study, 32 have received rlFN-α2a continuously for a median of 5 years. Patients received 3 million units of rlFN-α2a subcutaneously (SC) daily for 6 months, followed, in responding patients, by the same dose three times weekly. Twenty-one patients (40%) discontinued IFN after a median of 29 months, seven of whom developed resistant disease in association with anti-IFN antibodies. Treatment produced high response rates: complete response plus partial response (CR + PR) = 40 of 53 (76%), CR + PR + minor response (MR) = 43 of 53 (82%), with no differences in response rates between patients with and without splenectomy. Sixteen patients who had MR at 18 months had PR with prolonged treatment, nine of whom had a significant further reduction in the hairy cell infiltrate in the bone marrow (BM). The median granulocyte and platelet counts have continued to increase and the median serum soluble interleukin-2 receptor (slL-2R) level has continued to decrease with prolonged treatment. Two patients developed erythrocytosis that may be treatment related, but no other new toxicities were noted with prolonged treatment. We conclude that prolonged, continuous rlFN-α2a treatment has acceptable toxicity, is not associated with late development of IFN resistance, and results in continued hematologic improvement with time on treatment. This is a US government work. There are no restrictions on its use.

Published
1991
Full Text
View/download PDF

28. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.

Author

Jing Chen, Pise-Masison, Cynthia A., Shih, Joanna H., Morris, John C., Janik, John E., Conlon, Kevin C., Keating, Anne, and Waldman, Thomas A.

Subjects
*MOUSE leukemia, *ANTINEOPLASTIC agents, *ALEMTUZUMAB, *ADULT T-cell leukemia, *LYMPHOCYTES, *GENE expression
Abstract

Adult T-cell leukemia (ATL) is an aggressive malignancy of CD4+CD25+ lymphocytes caused by human 1-cell lymphotropic virus type 1. Currently, there is no accepted curative therapy for ATL. In gene expression profiling, the antiapoptotic protein survivin (BIRC5) demonstrated a striking increase in ATL, and its expression was increased in patient ATL cells resistant to the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). In this study, we investigated the antitumor activity of a small-molecule survivin suppressant YM155 alone and in combination with alemtuzumab in a murine model of human ATL (MET-1). Both YM155 alone and its combination with alemtuzumab demonstrated therapeutic efficacy by lowering serum soluble IL-2Rα (sIL-2Rα) levels (P< .001) and prolonged the survival of tumor-bearing mice (P< .0001). Moreover, the combination of YM155 with alemtuzumab demonstrated markedly additive antitumor activity by significantly lowering serum sIL-2Rα levels and improving the survival of leukemia-bearing mice compared with monotherapy with either YM155 (P < .001) or alemtuzumab (P < .05). More significantly, all mice that received the combination therapy survived and were tumor free >6 months after treatment. Our data support a clinical trial of the combination of YM155 with alemtuzumab in ATL. This trial was registered at www.clinicaltrials.gov as #NCT00061 048. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results